Zosano Pharma (NASDAQ:ZSAN) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 14th.
Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.16). On average, analysts expect Zosano Pharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
NASDAQ:ZSAN traded down $0.03 during trading hours on Thursday, hitting $3.39. The stock had a trading volume of 200 shares, compared to its average volume of 1,759,932. Zosano Pharma has a 1-year low of $1.85 and a 1-year high of $6.65. The company has a market capitalization of $58.05 million, a price-to-earnings ratio of -0.90 and a beta of 2.62.
In related news, CEO John Peter Walker purchased 100,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average price of $3.50 per share, with a total value of $350,000.00. Following the completion of the transaction, the chief executive officer now owns 280,228 shares of the company’s stock, valued at $980,798. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.71% of the stock is currently owned by company insiders.
ZSAN has been the subject of several recent research reports. Maxim Group initiated coverage on shares of Zosano Pharma in a research report on Wednesday, April 17th. They issued a “buy” rating and a $8.00 price objective for the company. ValuEngine raised shares of Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, Cantor Fitzgerald initiated coverage on shares of Zosano Pharma in a research report on Monday, April 22nd. They issued an “overweight” rating and a $3.66 price objective for the company.
About Zosano Pharma
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Featured Story: Momentum Indicators
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.